ASCO 2024 | IMC-F106C, a novel PRAME × CD3 ImmTAC, in metastatic cutaneous melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from the Phase I trial (NCT04262466) evaluating IMC-F106C, a novel ImmTAC bispecific protein (PRAME × CD3), in patients with HLA-A*02:01-positive metastatic cutaneous melanoma (mCM) previously treated with immune checkpoint inhibitors. IMC-F106C demonstrated significant clinical activity and T cell activation, particularly in PRAME-positive patients. The treatment was well tolerated, with no drug-related discontinuations or deaths. The promising results, including enhanced progression-free survival and overall survival, support the initiation of a Phase III PRISM-MEL301 trial (NCT06112314). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.